G vs PLXS

Genpact presents a classic value-trap profile, characterized by a stable Piotroski F-Score of 4/9 and a current price ($34.32) trading very close to its Graham Number ($32.47). While the company maintains a strong ROE of 22.37% and a very attractive forward P/E of 7.73, these fundamentals are offset by a disastrous technical trend (0/100) and bearish insider activity. The core business faces significant existential risks from generative AI, which the 10-K explicitly notes could replace existing services and reduce demand. Consequently, the deep valuation discount is likely a reflection of the market pricing in structural industry disruption.

PLXS exhibits exceptional financial health with a perfect Piotroski F-Score of 9/9 and a very low Debt/Equity ratio of 0.13. However, the stock is significantly overvalued, trading at $222.88, which is well above both its Graham Number ($89.63) and its growth-based Intrinsic Value ($167.76). While the earnings track record is stellar with consistent beats over 25 quarters, bearish insider sentiment and a weak technical trend suggest a potential price correction. The disconnect between the 'Buy' analyst recommendation and a target price ($200.80) that is lower than the current market price further supports a cautious stance.